Showing 1951-1960 of 2659 results for "".
- Nova Eye to Feature Several Presentations and Posters Related to iTrack Canaloplasty at 2024 ESCRS Annual Congresshttps://modernod.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/Nova Eye Medical has announced that the company’s proprietary canaloplasty technology platform (iTrack and iTrack Advance) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons
- Spryte Medical Receives Breakthrough Device Designation from FDA for Neuro OCT Technologyhttps://modernod.com/news/spryte-medical-receives-breakthrough-device-designation-from-fda-for-neuro-optical-coherence-tomography-noct-technology/2482373/Spryte Medical announced that its neuro Optical Coherence Tomography (nOCT) technology has been granted Breakthrough Device Designation by the FDA. This recognition underscores the potential of nOCT in neurointervention and cerebrovascular treatment. The FDA’s
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- Vabysmo Receives CHMP Recommendation for RVO Indicationhttps://modernod.com/news/roches-vabysmo-gets-chmp-recommendation-for-rvo-indication/2482337/Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of Vabysmo (faricimab) marketing authorization to include the treatment of visual impairment caused by macular edema secondary to retin
- EMA’s CHMP Issues Negative Opinion of Syfovre for GA; Apellis to Seek Re-Examinationhttps://modernod.com/news/emas-chmp-issues-negative-opinion-for-syfovre-for-ga-apellis-to-seek-re-examination/2482336/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of Apellis’s intravitreal pegcetacoplan for the treatment of geographic atrophy (GA). “Although th
- Karen Petrou Appointed Board Chair of the Foundation Fighting Blindnesshttps://modernod.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/The Foundation Fighting Blindness announced the appointment of Karen Petrou as Board Chair, effective July 1, 2024. Petrou succeeds David Brint, who is retiring after 8 years of service. Ms. Petrou’s becomes the third person to hold the position in the Foundation&rs
- Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)https://modernod.com/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel/2482324/The FDA has granted priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel), an investigational encapsulated cell therapy for the treatment of Macular Telangiectasia Type 2 (MacTel). The designation m
- B+L Introduces INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/Bausch + Lomb has introduced 'INFUSE for Astigmatism' daily disposable contact lenses in the US. Engineered with a next-generation lens material infused with ProBalance Technology and the company’s proprietary OpticAlign design, Bausch + Lomb says INFUSE for
- Nidek Launches the RS-1 Glauvas Optical Coherence Tomography Devicehttps://modernod.com/news/nidek-launches-the-rs-1-glauvas-optical-coherence-tomography/2482304/Nidek has launched the RS-1 Glauvas Optical Coherence Tomography (OCT). The RS-1 Glauvas has up to 250kHz scan speed, wide and deep area imaging, operability, and deep learning-based analytics. The incorporation of 250,000 A-scans/s accelerates the workflow by reducing capture
- LambdaVision Closing of Seed Round to Advance Artificial Retina Preclinical Studieshttps://modernod.com/news/lambdavision-closing-of-seed-round-to-advance-artificial-retina-preclinical-studies/2482302/LambdaVision, which is developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round. The proceeds will be used to fund LambdaVision’s GMP manufacturing scale up and critical IN